Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first in class, proof-of-concept, single arm phase 2...

por Lee, Jung-Min, Nair, Jayakumar, Zimmer, Alexandra, Lipkowitz, Stanley, Annunziata, Christina M., Merino, Maria J., Swisher, Elizabeth M., Harrell, Maria I., Trepel, Jane B., Lee, Min-Jung, Bagheri, Mohammad H., Botesteanu, Dana-Adriana, Steinberg, Seth M., Minasian, Lori, Ekwede, Irene, Kohn, Elise C.
Publicado 2018